RESUMEN
BACKGROUND: There is a need to identify, as early as possible, infants who are at risk for long-term neurological morbidity. METHODS: To predict neurodevelopment outcome of preterm infants <30 weeks' gestation in a population of 100 infants, we used several neonatal and neurobehavioral tests, including cranial ultrasonography, the Prechtl neurological test, quality of spontaneous general movements, and quality of sleep-wake organization. RESULTS: The Prechtl test at corrected term age and findings on cranial sonograms both had high specificity, but the Prechtl test had better overall positive predictive power for normal neurological and developmental outcomes at 2 years' corrected age. Developmental changes in sleep and the amount of indeterminate sleep did not correlate with outcome. Scoring general movement quality did not predict outcome and did not augment the positive predictive power of the Prechtl test. CONCLUSIONS: The Prechtl test at corrected term age (independent of the other tests) is the best positive predictor of normal neurological outcome and Bayley test results at 2 years' corrected age.
Asunto(s)
Discapacidades del Desarrollo/diagnóstico , Recien Nacido Prematuro , Método Doble Ciego , Ecoencefalografía , Femenino , Humanos , Recién Nacido , Masculino , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: To compare synchronized intermittent mandatory ventilation (SIMV) and conventional intermittent mandatory ventilation (IMV) in neonates. STUDY DESIGN: Prospective, multicenter, randomized clinical trial. SETTING: Level III neonatal intensive care units at six university or children's hospitals. PATIENTS: Three hundred twenty-seven infants receiving conventional IMV for respiratory distress syndrome, pneumonia, or meconium aspiration pneumonitis were randomly assigned a 7.5 +/- 6 hours of age to either continue with IMV or change to SIMV. Infants assigned to each mode of ventilation had similar birth weight (BW), gestational age, and Apgar scores at birth, and similar oxygenation indexes at randomization. They received similar surfactant therapy and had similar incidence of sepsis, seizures, secondary pneumonia, and necrotizing enterocolitis. In the infants with BW less than 1000 gm, more infants receiving IMV had surgical ligation of their patent ductus arteriosus than did those receiving SIMV (27 vs. 7 %; p = 0.02). ANALYSIS: Data was analyzed overall for all infants and also separately within three BW groups: less than 1000 gm, 1000 to 2000 gm, and more than 2000 gm. The 1000 to 2000 gm BW group was further analyzed in subgroups weighing 1000 to 1499 gm and 1500 to 2000 gm. RESULTS: In all infants, at 1 hour after randomization, the infants receiving SIMV had a lower mean airway pressure than those receiving IMV (8.08 +/- 2.15 vs. 8.63 +/- 2.59; p<0.05), with similar fractions of inspired oxygen and oxygenation indexes. Infants whose BW was 1000 to 2000 gm at 0.5 hour required a lower fraction of inspired oxygen with SIMV than with IMV (0.52 +/- 0.20 vs. 0.62 +/- 0.27; p<0.05) and had better oxygenation at 1 hour, as shown by lower oxygenation indexes with SIMV than with IMV (6.14 +/- 4.17 vs. 9.42 +/- 8.41; p = 0.01). Infants whose BW was 1000 to 2000 gm received a lower number of unit doses of sedative/analgesic drugs per infant during the first 4 days of SIMV than did infants receiving IMV (3.8 +/- 3.4 vs 6.3 +/- 5.5 unit doses; p = 0.02). Infants whose BW was more than 2000 gm had a shorter duration of mechanical ventilation with SIMV than with IMV (median, 72 vs 93 hours; p = 0.02). Three of the forty-six infants receiving IMV but none of the 47 infants receiving SIMV required extracorporeal membrane oxygenation. In the infants with BW less than 1000 gm, fewer infants treated with SIMV required supplemental oxygen at 36 weeks of postconceptional age than did those treated with IMV (47 vs 72%; p<0.05). In 83 infants whose lungs were mechanically ventilated for 14 days or longer, all with BW less than 2000 gm, those treated with SIMV regained their BW earlier than those treated with IMV (median, 21.5 vs 29 days; p<0.01). There were no differences in the rates of death, intraventricular hemorrhage (grades III and IV), air leak, need for pharmacologic paralysis, or need for supplemental oxygen at 28 days. CONCLUSIONS: We found that SIMV was at least as efficacious as conventional IMV, and may have improved certain outcomes in BW-specific groups.
Asunto(s)
Respiración Artificial/métodos , Femenino , Humanos , Recién Nacido de Bajo Peso , Recién Nacido , Enfermedades del Recién Nacido/mortalidad , Enfermedades del Recién Nacido/terapia , Masculino , Estudios Prospectivos , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
As part of a blinded, randomized, placebo-controlled study of dexamethasone therapy in 27 preterm infants with bronchopulmonary dysplasia, we investigated the effect of 7 days of high-dose glucocorticoid therapy on the hypothalamic-pituitary-adrenal axis. Before therapy the median basal cortisol concentration in all infants was 8.2 micrograms/dl (226 nmol/L). After stimulation with 1-24 ACTH, the serum cortisol concentration rose in all infants to a median concentration of 23.5 micrograms/dl (649 nmol/L), resulting in a median rise of 13.4 micrograms/dl (37 nmol/L). Immediately after 7 days of glucocorticoid therapy basal and peak cortisol concentrations were significantly decreased in the dexamethasone group. The rise in serum cortisol following 1-24 ACTH, however, remained equivalent in both groups. Ten days after the end of therapy basal and peak cortisol concentrations in the dexamethasone group had returned to levels equivalent to those seen in the placebo group. Weight gain was markedly diminished while the infants were receiving dexamethasone. Weight gains were, however, equivalent 10 days after the end of treatment. These data indicate that 7 days of dexamethasone therapy has significant but short-term effects on cortisol secretion and possibly on weight gain.
Asunto(s)
Dexametasona/farmacología , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Recien Nacido Prematuro/fisiología , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Displasia Broncopulmonar/tratamiento farmacológico , Ensayos Clínicos como Asunto , Femenino , Humanos , Hidrocortisona/sangre , Recién Nacido , Masculino , Distribución Aleatoria , Aumento de Peso/efectos de los fármacosRESUMEN
To assess the risk of long-term sequelae after acquired cytomegalovirus (CMV) infection in premature and sick term infants, 55 CMV infected patients were matched prospectively with 55 control patients and these matched pairs were evaluated at 3 years of age. Sensorineural hearing losses were present in four of 43 CMV infected patients (all mild-moderate) and in two of 43 controls (one severe). The incidence of neurologic sequelae was not increased in CMV infected patients with birth weight greater than 2000 gm. Among patients with birth weight less than 2001 gm, moderately abnormal EEGs were found in four (17%) of 23 CMV infected patients and in one (4%) of 23 controls, and severe handicaps occurred in four (14%) of 29 CMV infected patients and in two (7%) of 29 controls. Severe handicaps in premature infants were significantly (P less than 0.05) associated with early onset of CMV excretion (less than 8 weeks of age) and severe cardiopulmonary disease. Among the premature infants who were documented early excretors, three of 13 had severe neuromuscular impairment, four of 13 had severe handicaps (DQ less than 70, severe neuromuscular impairment, or profound loss of vision or hearing), and an additional four had DQs of 70 to 79. Among their matched control subjects, none of 13 had severe neuromuscular impairment, two of 13 had severe handicaps, and an additional two had DQs between 70 and 79. None of the premature infants who were documented late excretors (greater than or equal to 8 weeks of age) had any neurologic sequelae. The risk of neurologic sequelae and handicap may be increased in premature infants with onset of CMV excretion in the first 2 months of life.
Asunto(s)
Infecciones por Citomegalovirus/complicaciones , Enfermedades del Recién Nacido/complicaciones , Enfermedades del Prematuro/complicaciones , Personas con Discapacidad , Electroencefalografía , Estudios de Seguimiento , Pérdida Auditiva Sensorineural/etiología , Humanos , Recién Nacido , Microcefalia/etiología , Examen Neurológico , Estudios Prospectivos , RiesgoRESUMEN
Sodium nitroprusside was administered to 58 neonates, including 11 with severe respiratory distress syndrome, 15 with persistent pulmonary hypertension of the newborn, 28 with clinical shock, three with systemic hypertension, and two with pulmonary hypoplasia, all refractory to conventional intensive therapy. Nitroprusside was infused at 0.2 to 6.0 micrograms/kg/min for periods of 10 minutes to 126 hours. Infants with severe respiratory distress syndrome had increased PaO2 and decreased PaCO2 or peak inspiratory pressure, and nearly all (82%) survived. Infants with persistent pulmonary hypertension of the newborn had variable responses; improvement did not correlate with survival, but survival (47%) was identical to that in an earlier series of infants given tolazoline. Infants in shock had improved perfusion, urine output, and serum bicarbonate levels, and these responses were significantly related to survival. Hypertension was controlled in all three hypertensive infants. Adverse effects were very uncommon. Toxic effects were not observed. Sodium nitroprusside is effective and can be used safely in circulatory disorders in the neonate.
Asunto(s)
Ferricianuros/uso terapéutico , Enfermedades del Recién Nacido/tratamiento farmacológico , Nitroprusiato/uso terapéutico , Bicarbonatos/sangre , Dióxido de Carbono/sangre , Evaluación de Medicamentos , Hemodinámica/efectos de los fármacos , Humanos , Recién Nacido , Enfermedades del Recién Nacido/mortalidad , Enfermedades del Recién Nacido/fisiopatología , Infusiones Parenterales , Inhalación , Pulmón/efectos de los fármacos , Enfermedades Pulmonares/tratamiento farmacológico , Meconio , Nitroprusiato/administración & dosificación , Nitroprusiato/efectos adversos , Oxígeno/sangre , Síndrome de Circulación Fetal Persistente/tratamiento farmacológico , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Choque/tratamiento farmacológicoRESUMEN
Eighteen of 106 (17%) infants of seropositive mothers, with birth weights less than 1500 gm, acquired cytomegalovirus from a maternal source. Neutropenia, lymphocytosis, thrombocytopenia, and hepatosplenomegaly developed in some infants concomitant with the onset of CMV excretion. Infected infants who excreted CMV at less than 7 weeks of age had longer oxygen requirements than infants who did not excrete CMV until they were older. Passively derived maternal antibody to CMV fell more rapidly over the first few months of life in sick premature infants than would be expected in term infants. Among six infected premature infants, five had undetectable antibody titers when CMV excretion began. Loss of passively acquired antibody and early excretion of virus appear to be associated with symptomatic CMV infections in premature infants of seropositive mothers.
Asunto(s)
Infecciones por Citomegalovirus/etiología , Enfermedades del Prematuro/etiología , Intercambio Materno-Fetal , Anticuerpos Antivirales/análisis , Citomegalovirus/inmunología , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/inmunología , Femenino , Humanos , Recién Nacido , Enfermedades del Prematuro/inmunología , EmbarazoRESUMEN
We designed an in vitro assay to detect the presence of lactose in the tracheal aspirates of premature, ventilator-dependent infants. This method was employed to identify recurrent, unrecognized aspiration, which could prolong the requirements for ventilator support and contribute to the development of chronic lung disease. One hundred five determinations of lactose were performed on the tracheal fluid obtained from 42 ventilator-dependent infants who were receiving enteral feedings. There was a wide range of lactose levels (0 to 3,270 nmol lactose/ml tracheal aspirate). Six infants had samples that were highly suggestive of aspiration (greater than 200 nmol lactose/ml tracheal aspirate). Twenty infants had questionably positive samples (25 to 200 nmol lactose/ml tracheal aspirate), and 16 infants had samples that were considered negative for aspiration (less than 25 nmol lactose/ml tracheal aspirate).
Asunto(s)
Jugo Gástrico/análisis , Enfermedades del Prematuro/diagnóstico , Lactosa/análisis , Neumonía por Aspiración/diagnóstico , Nutrición Enteral , Glucosa/análisis , Humanos , Recién Nacido , Métodos , TráqueaRESUMEN
Forty-five term infants who had a "near miss" for SIDS were studied with a continuous overnight polygraphic recording of endoesophageal pH, respiration, and ECG. Recordings were examined for occurrences of GER and for central apnea of 10 seconds or greater duration. There were 341 apneic events greater than or equal to 10 seconds recorded in 46 studies, with a mean of 7 +/- 7. In 91% of the infants, no apneas exceeded 15 seconds. Only 31 episodes of apnea greater than or equal to 10 seconds occurred during GER: in two of these episodes the apneic event was greater than or equal to 15 seconds. Twenty-four of the 31 apneas greater than or equal to 10 seconds during periods of pH less than 4 occurred in one infant. A total of 356 precipitous pH drops was recorded (mean 8.7 +/- 7.4). The pH drops occurred most frequently when the patient appeared to be awake (73%), and in 84% of events there was movement before and during the pH change. We conclude that the majority of these near miss SIDS infants had GER associated with movement during awake periods, without any temporal relationship to apnea. Although reflex apnea following GER may be seen in some term infants, this problem may be more significant for the immature infant.
Asunto(s)
Apnea/etiología , Reflujo Gastroesofágico/fisiopatología , Movimiento , Muerte Súbita del Lactante/fisiopatología , Esófago , Femenino , Humanos , Concentración de Iones de Hidrógeno , Lactante , Recién Nacido , Masculino , Monitoreo Fisiológico , Vigilia/fisiologíaAsunto(s)
Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Tolazolina/uso terapéutico , Preescolar , Discapacidades del Desarrollo/etiología , Humanos , Recién Nacido , Síndrome de Dificultad Respiratoria del Recién Nacido/complicaciones , Síndrome de Dificultad Respiratoria del Recién Nacido/mortalidad , Tolazolina/efectos adversosAsunto(s)
Conducto Arterioso Permeable/tratamiento farmacológico , Prostaglandinas E/administración & dosificación , Conducto Arterioso Permeable/cirugía , Femenino , Humanos , Recién Nacido , Cuidados Preoperatorios , Tetralogía de Fallot/tratamiento farmacológico , Tetralogía de Fallot/cirugía , Transposición de los Grandes Vasos/tratamiento farmacológico , Transposición de los Grandes Vasos/cirugíaRESUMEN
Thirty-nine critically ill infants with pulmonary disease received tolazoline because of severe hypoxemia refractory to administration of 100% O2 and mechanical ventilation. Twenty-seven (69%) of the infants responded with an increase in PaO2 greater than or equal to 20 torr in the first umbilical arterial gas after completion of the initial ten-minute infusion (1 to 2 mg/kg) of the drug. A response was not correlated with survival. The overall survival was 46%, essentially unchanged from our previous report (44%). Infants with hyaline membrane disease had the poorest survival rate (33%). Complications associated with the use of tolazoline occurred in 82% of the infants. A hypotensive reaction, defined as a 25% decrease in mean arterial pressure from the pre-tolazoline level, occurred in 67% of the infants, and more commonly in the infants with RDS (87%). In 11 infants who did not respond to the initial dose of tolazoline, the dose was increased up to 10 mg/kg/hour; only one infant responded, and eight (73%) had a hypotensive reaction.
Asunto(s)
Hipoxia/terapia , Enfermedades del Recién Nacido/complicaciones , Enfermedades Pulmonares/complicaciones , Tolazolina/uso terapéutico , Dióxido de Carbono/sangre , Humanos , Enfermedad de la Membrana Hialina/complicaciones , Enfermedad de la Membrana Hialina/mortalidad , Hipoxia/tratamiento farmacológico , Hipoxia/etiología , Recién Nacido , Enfermedades del Recién Nacido/mortalidad , Inhalación , Enfermedades Pulmonares/mortalidad , Meconio , Oxígeno/sangre , Terapia por Inhalación de Oxígeno , Respiración Artificial , Síndrome de Dificultad Respiratoria del Recién Nacido/complicaciones , Síndrome , Tolazolina/efectos adversos , Arterias UmbilicalesRESUMEN
Infants under radiant warmers have large increases in insensible water loss compared with infants in single wall incubators. To answer the question of whether or not a minimal rate of oxygen consumption could be achieved under overhead radiant warmers, we measured oxygen consumption, carbon dioxide production, and abdominal skin, cheek, rectal, thigh, and environmental temperature in ten healthy newborn infants in incubators and radiant warmers, using each infant as his/her own control. The minimal VO2 ranged from 4.41 to 8.87 and from 4.35 to 9.06 cc/kg/minute in the incubator and radiant warmer, respectively. The differences were clearly not significant (paired Student t-test, P greater than 0.60). There were no significant differences between the respiratory quotients, VCO2, or abdominal skin, check, rectal or environmental temperatures. These data support the hypothesis that a thermoneutral environment can be provided with a radiant warmer and imply that large increases in insensible water loss can occur without affecting minimal oxygen consumption.